Terms: = Kidney tumors AND PPFIBP1, L2, 8496, ENSG00000110841, hSGT2, hSgt2p AND Prognosis
18 results:
1. CD44 Is a Prognostic Biomarker Correlated With Immune Infiltrates and Metastasis in Clear Cell Renal Cell Carcinoma.
Ma J; Wu R; Chen Z; Zhang Y; Zhai W; Zhu R; Zheng J
Anticancer Res; 2023 Aug; 43(8):3493-3506. PubMed ID: 37500138
[TBL] [Abstract] [Full Text] [Related]
2. The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma.
Mondorf Y; Mikuteit M; Ivanyi P; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief CG; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Steffens S; Erlmeier F
Urol Int; 2022; 106(11):1168-1176. PubMed ID: 35654002
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic importance of SUVmax values evaluated by 18F-FDG-PET/CT before nivolumab treatment in patients with metastatic renal cell carcinoma.
Gulturk I; Yilmaz M; Tacar SY; Tural D
Q J Nucl Med Mol Imaging; 2023 Sep; 67(3):223-229. PubMed ID: 34881845
[TBL] [Abstract] [Full Text] [Related]
4. NGS-analysis to the rescue: dual checkpoint inhibition in metastatic osteosarcoma - a case report and review of the literature.
Nuytemans L; Sys G; Creytens D; Lapeire L
Acta Clin Belg; 2021 Apr; 76(2):162-167. PubMed ID: 31635553
[No Abstract] [Full Text] [Related]
5. Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth.
Roumenina LT; Daugan MV; Noé R; Petitprez F; Vano YA; Sanchez-Salas R; Becht E; Meilleroux J; Clec'h BL; Giraldo NA; Merle NS; Sun CM; Verkarre V; Validire P; Selves J; Lacroix L; Delfour O; Vandenberghe I; Thuilliez C; Keddani S; Sakhi IB; Barret E; Ferré P; Corvaïa N; Passioukov A; Chetaille E; Botto M; de Reynies A; Oudard SM; Mejean A; Cathelineau X; Sautès-Fridman C; Fridman WH
Cancer Immunol Res; 2019 Jul; 7(7):1091-1105. PubMed ID: 31164356
[TBL] [Abstract] [Full Text] [Related]
6. Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma.
Angenard G; Merdrignac A; Louis C; Edeline J; Coulouarn C
Dig Liver Dis; 2019 Sep; 51(9):1337-1343. PubMed ID: 31040073
[TBL] [Abstract] [Full Text] [Related]
7. JQ1, a BET-bromodomain inhibitor, inhibits human cancer growth and suppresses PD-L1 expression.
Liu K; Zhou Z; Gao H; Yang F; Qian Y; Jin H; Guo Y; Liu Y; Li H; Zhang C; Guo J; Wan Y; Chen R
Cell Biol Int; 2019 Jun; 43(6):642-650. PubMed ID: 30958600
[TBL] [Abstract] [Full Text] [Related]
8. Immune infiltration in renal cell carcinoma.
Zhang S; Zhang E; Long J; Hu Z; Peng J; Liu L; Tang F; Li L; Ouyang Y; Zeng Z
Cancer Sci; 2019 May; 110(5):1564-1572. PubMed ID: 30861269
[TBL] [Abstract] [Full Text] [Related]
9. The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.
Zhao SG; Lehrer J; Chang SL; Das R; Erho N; Liu Y; Sjöström M; Den RB; Freedland SJ; Klein EA; Karnes RJ; Schaeffer EM; Xu M; Speers C; Nguyen PL; Ross AE; Chan JM; Cooperberg MR; Carroll PR; Davicioni E; Fong L; Spratt DE; Feng FY
J Natl Cancer Inst; 2019 Mar; 111(3):301-310. PubMed ID: 30321406
[TBL] [Abstract] [Full Text] [Related]
10. Overexpression of low density lipoprotein receptor-related protein 1 (LRP1) is associated with worsened prognosis and decreased cancer immunity in clear-cell renal cell carcinoma.
Feng C; Ding G; Ding Q; Wen H
Biochem Biophys Res Commun; 2018 Sep; 503(3):1537-1543. PubMed ID: 30033103
[TBL] [Abstract] [Full Text] [Related]
11. Variation in nuclear size and PD-L2 positivity correlate with aggressive chromophobe renal cell carcinoma.
Mostafa ME; Abdelkader A; Kuroda N; Pérez-Montiel D; Banerjee A; Hes O; Iczkowski KA
Ann Diagn Pathol; 2018 Jun; 34():31-35. PubMed ID: 29661724
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic impact of PD-1 and its ligands in renal cell carcinoma.
Erlmeier F; Weichert W; Schrader AJ; Autenrieth M; Hartmann A; Steffens S; Ivanyi P
Med Oncol; 2017 Jun; 34(6):99. PubMed ID: 28432616
[TBL] [Abstract] [Full Text] [Related]
13. PD-L1 expression in papillary renal cell carcinoma.
Motoshima T; Komohara Y; Ma C; Dewi AK; Noguchi H; Yamada S; Nakayama T; Kitada S; Kawano Y; Takahashi W; Sugimoto M; Takeya M; Fujimoto N; Oda Y; Eto M
BMC Urol; 2017 Jan; 17(1):8. PubMed ID: 28086852
[TBL] [Abstract] [Full Text] [Related]
14. Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine prognosis in Clear Cell Renal Cell Carcinoma.
Matsushita H; Sato Y; Karasaki T; Nakagawa T; Kume H; Ogawa S; Homma Y; Kakimi K
Cancer Immunol Res; 2016 May; 4(5):463-71. PubMed ID: 26980598
[TBL] [Abstract] [Full Text] [Related]
15. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H
Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193
[TBL] [Abstract] [Full Text] [Related]
16. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract] [Full Text] [Related]
17. Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer.
Giraldo NA; Becht E; Pagès F; Skliris G; Verkarre V; Vano Y; Mejean A; Saint-Aubert N; Lacroix L; Natario I; Lupo A; Alifano M; Damotte D; Cazes A; Triebel F; Freeman GJ; Dieu-Nosjean MC; Oudard S; Fridman WH; Sautès-Fridman C
Clin Cancer Res; 2015 Jul; 21(13):3031-40. PubMed ID: 25688160
[TBL] [Abstract] [Full Text] [Related]
18. MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients.
Gámez-Pozo A; Antón-Aparicio LM; Bayona C; Borrega P; Gallegos Sancho MI; García-Domínguez R; de Portugal T; Ramos-Vázquez M; Pérez-Carrión R; Bolós MV; Madero R; Sánchez-Navarro I; Fresno Vara JA; Espinosa Arranz E
Neoplasia; 2012 Dec; 14(12):1144-52. PubMed ID: 23308047
[TBL] [Abstract] [Full Text] [Related]
